Abstract
Introduction Myelodysplastic syndromes (MDS) are genomically complex clonal hematopoietic stem cell neoplasms leading to myelodysplasia and ineffective hematopoiesis.1,2 MDS is a disease of older age, clinically manifesting as symptomatic cytopenias with an added propensity for transformation to acute myeloid leukemia (AML).3 The treatment of MDS is based on a risk-adapted approach per the International Prognostic Scoring System (IPSS)4 or the modified IPSS-R.5 Allogeneic stem cell transplantation (ASCT) is the only curative strategy, but most patients are not eligible due to their age or other comorbidities.6 In these patients, hypomethylating agents (HMA, either decitabine or azacitidine) are the mainstay of therapy to either alleviate cytopenias or impede disease progression. 7 Decitabine (DEC) and azacitidine (AZA) are approved to treat patients with MDS, including previously treated and untreated, de novo, and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk IPSS groups.7
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
